Southlake, TX — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has been issued a notice of patent allowance from the European Patent Office.
To date, HeartSciences has been granted or allowed 41 patents including 9 in the United States. Issued international patents are across key countries including China, Brazil, Canada, India, South Korea, Mexico, and key European markets such as Germany, France, UK, Italy and the Netherlands. The European Patent Office has 39 European member countries, and the patent allowance covers quantification by an ECG of key echocardiographic measures of heart function using AI methods, which has never been possible with a conventional ECG.
"Millions of ECGs are performed worldwide every week and the ECG is by far the most ubiquitous cardiac test. The addition of cardiac dysfunction detection to the ECG is expected to provide significant benefit to healthcare providers and health systems around the world. HeartSciences MyoVista could play a significant role in heart health screening worldwide," said Andrew Simpson, CEO of HeartSciences. "AI continues to revolutionize medical devices and health systems and we are delighted to add another AI patent for an ECG. Given the huge market opportunity, protection of our intellectual property and patents in major markets is core to the Company as it provides intrinsic value to HeartSciences."
Investor contact
Mark Komonoski, Integrous Communications · 877-255-8483 · [email protected]